Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
13/07/2026 16:11
BRIEF-Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial July 13 (Reuters) - Zelluna ASA ZLNA.OL:
FIRST PATIENT DOSED WITH ZI-MA4-1 IN ZIMA-101 PHASE 1 TRIAL
INITIAL CLINICAL DATA FROM ZIMA-101 EXPECTED FROM MID-2026
Source text: ID:nGNE1TdNG1
Further company coverage: ZLNA.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant